Global /Bahamas /Healthcare /Biotechnology /NYMXF

Nymox Pharmaceutical Corp.

NYMXF

• OTCMKTS: NYMXF • Delayed

0.0553USD 33%

As of 16 June 2026, Nymox Pharmaceutical Corp. has a market cap of $5.23M USD, ranking #44316 globally and #3 in Bahamas. It ranks #3926 in the Healthcare sector, and #774 in the Biotechnology industry.

Global Rank

44316

Country Rank

Sector Rank

3926

Industry Rank

774

Key Stats

Market Cap

$5.23MUSD

Enterprise Value

$8.44MUSD

EBITDA (TTM)

-$4.28MUSD

Net Income (TTM)

-$4.49MUSD

PB Ratio

-0.8

Company Profile

Country (HQ)

Bahamas

Sector

Healthcare

Industry

Biotechnology

CEO

Paul Averback open_in_new

Employees

Founded

1989

Website

nymox.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
33%	-34%	-42%	-39%	-45%	-45%	18K%	-90%	-98%

News

Markets

Exchange	Ticker	Price	Quotes
OTC Markets (OTCMKTS / OTC) MIC: OTCM PRIMARY	NYMXF Nymox Pharmaceutical Corp ISIN: BSP733981026 Shares Out.: Shares Outstanding: 94.54M¹ Shares Float: 51.373M² TV: TradingView: OTC: NYMXF SA: Stock Analysis: OTC: NYMXF YF: Yahoo Finance: NYMXF GF: Google Finance: OTCMKTS: NYMXF BA: Barron's: NYMXF MS: Morningstar: PINX: NYMXF	0.0553 USD	TV: TradingView: OTC: NYMXF SA: Stock Analysis: OTC: NYMXF YF: Yahoo Finance: NYMXF GF: Google Finance: OTCMKTS: NYMXF BA: Barron's: NYMXF MS: Morningstar: PINX: NYMXF

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Nymox Pharmaceutical Corp.

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert for determining smoking status; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer’s disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.

Similar Companies

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 3M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 3M%	19.0	United States
argenx SE EBR: ARGX	$47.89B 41.39B EUR 916K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$45.02B 68.19T KRW 861K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.64B 60.27B AUD 815K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.17B 33.71B CHF 806K%	37.2	Switzerland

chevron_leftBack